These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9613080)

  • 1. [Treatment and prevention of hyper- and dyslipidemia with magnesium-containing drugs].
    Shilov AM; Sviatov IS; Chubarov MV; Sanodze ID
    Klin Med (Mosk); 1998; 76(4):35-7. PubMed ID: 9613080
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term administration of tyquanol in the treatment of patients with ischemic heart disease in combination with hyperlipidemia].
    Panchenko VM; Ershov AA; Isaev VA
    Klin Med (Mosk); 2003; 81(3):40-2. PubMed ID: 12698850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of nicotinic acid in the treatment of atherosclerosis and atherogenic dyslipidemia].
    Aronov DM
    Klin Med (Mosk); 1996; 74(9):48-52. PubMed ID: 9121091
    [No Abstract]   [Full Text] [Related]  

  • 4. Dose-related cardiac electrophysiological effects of intravenous magnesium. A double-blind placebo-controlled dose-response study in patients with paroxysmal supraventricular tachycardia.
    Christiansen EH; Frost L; Andreasen F; Mortensen P; Thomsen PE; Pedersen AK
    Europace; 2000 Oct; 2(4):320-6. PubMed ID: 11194599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of dyslipidemia.
    McCormick JJ; Deeg MA
    Am J Nurs; 2000 Feb; 100(2):55-60. PubMed ID: 10683645
    [No Abstract]   [Full Text] [Related]  

  • 6. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.
    Mosca L; Merz NB; Blumenthal RS; Cziraky MJ; Fabunmi RP; Sarawate C; Watson KE; Willey VJ; Stanek EJ
    Circulation; 2005 Feb; 111(4):488-93. PubMed ID: 15687138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
    Yamada K; Fujimoto S; Tokura T; Fukudome K; Ochiai H; Komatsu H; Sato Y; Hara S; Eto T
    Ren Fail; 2005; 27(4):361-5. PubMed ID: 16060120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coenzyme A and dyslipidemia. Note II. Rapid effects of CoA on primary and secondary hypertriglyceridemias].
    Consolo F; Di Tommaso G; Arrigo F; Trifirò A
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1927-30. PubMed ID: 1231874
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
    Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
    Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dyslipidemia at the turn of the century: optimism or scepticism?].
    Soska V
    Vnitr Lek; 2004 Oct; 50 Suppl 1():S71-5. PubMed ID: 15651145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients.
    Samman A; Imai C; Straatman L; Frolich J; Humphries K; Ignaszewski A
    J Heart Lung Transplant; 2005 Aug; 24(8):1008-13. PubMed ID: 16102434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
    Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
    Cas Lek Cesk; 2005; 144(11):737-41. PubMed ID: 16335699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of alimentary magnesium deficiency in development of nephrolithiasis and its correction with magnesium salts in rats].
    Spasov AA; Iezhitsa IN; Kharitonova MV; Kravchenko MS; Snigur GL
    Vopr Pitan; 2008; 77(6):62-71. PubMed ID: 19227867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipids, lipid-lowering drugs, and the risk of breast cancer.
    Eliassen AH; Colditz GA; Rosner B; Willett WC; Hankinson SE
    Arch Intern Med; 2005 Oct; 165(19):2264-71. PubMed ID: 16246993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on statins and other lipid-lowering drugs.
    Miller CA
    Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910
    [No Abstract]   [Full Text] [Related]  

  • 17. AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis.
    Jellinger PS; Dickey RA; Ganda OP; Mehta AE; Nguyen TT; Rodbard HW; Seibel JA; Shepherd MD; Smith DA;
    Endocr Pract; 2000; 6(2):162-213. PubMed ID: 11428356
    [No Abstract]   [Full Text] [Related]  

  • 18. Dyslipidemia in type 2 diabetes.
    Krauss RM; Siri PW
    Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
    Corsini A; Holdaas H
    Ren Fail; 2005; 27(3):259-73. PubMed ID: 15957541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of dyslipidemia in women and men.
    Haymart MR; Allen J; Blumenthal RS
    J Gend Specif Med; 1999; 2(6):37-42. PubMed ID: 11279870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.